Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic

References

• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
   PubMed Web of Science ®Google Scholar
• Carter JA, Ji X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res 2013;13:483-96
   PubMed Web of Science ®Google Scholar
• Qian Y, Song X, Zhang K, et al. Short-term disability in solid tumor patients with bone metastases and skeletal-related events. J Med Econ 2015;18:210-8
   PubMed Web of Science ®Google Scholar
• Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84
   PubMed Web of Science ®Google Scholar
• Body JJ, Pereira J, Sleeboom H, et al. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ 2015;17:711-21
   PubMed Web of Science ®Google Scholar
• Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective–prospective observational study – a cohort from 4 European countries. J Bone Oncol 2014;3:40-8
   PubMed Web of Science ®Google Scholar
• Luftner D, Lorusso V, Duran I, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus 2014;3:328
   PubMed Web of Science ®Google Scholar
• Hechmati G, Cure S, Gouepo A, et al. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ 2013;16:691-700
   PubMedGoogle Scholar
• Pereira J, Body JJ, Gunther O, et al. Cost of skeletal complications from bone metastases in six European countries. J Med Econ 2016;19:611-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, XGEVA (denosumab) summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed April 5, 2016
   Google Scholar
• European Medicines Agency, Zometa (zoledronic acid) summary of product characteristics. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf. Accessed April 5, 2016
   Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22
   PubMed Web of Science ®Google Scholar
• Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 2014;22:679-87
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-92
   PubMed Web of Science ®Google Scholar
• Czech Republic General Health Insurance Company. List of reimbursed health procedures. 2015. Czech Republic General Health Insurance https://www.vzp.cz/poskytovatele/ciselniky/zdravotni-vykony. Accessed July 28, 2016
   Google Scholar
• Expert Panel., Amgen data on file.
   Google Scholar
• Czech State Institute for Drug Control (SÚKL). List of reimbursed medicines. 2015. http://www.sukl.cz/sukl/seznam-cen-a-uhrad-lp-pzlu-k-1-12-2015. Accessed July 28, 2016
   Google Scholar
• Amgen. XGEVA (denosumab) summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. Accessed April 5, 2016
   Google Scholar
• Novartis Europharm Limited. Zometa (zoledronic acid) summary of product characteristics. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf. Accessed April 5, 2016
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 3. Value Health 2012;15:812-20
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474
   Web of Science ®Google Scholar
• Saad F, Gleason D, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68
   PubMed Web of Science ®Google Scholar
• Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82
   PubMed Web of Science ®Google Scholar
• Carter JA, Joshi A, Kaura S, et al. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. J Med Econ 2011;14:288-98
   PubMedGoogle Scholar
• De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005;13:975-86
   PubMed Web of Science ®Google Scholar
• De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005;27:1295-310
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
   PubMed Web of Science ®Google Scholar
• Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012;15:712-23
   PubMedGoogle Scholar
• Matza LS, Chung K, Van Brunt K, et al. Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ 2014;15:7-18
   PubMed Web of Science ®Google Scholar
• Skoupá J, Annemans L, Hájek P. Health economic data requirements and availability in the European Union: results of a survey among 10 European countries. Value Health 2014;4:53-7
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) program. SEER*Stat Database: incidence. http://seer.cancer.gov/seerstat. Accessed April 5, 2016
   Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006. Breast Cancer Res Treat 2012;131:231-8
   PubMed Web of Science ®Google Scholar
• Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis 2011;14:177-83
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) program. SEER*Stat Database: incidence. http://seer.cancer.gov/seerstat. Accessed April 5, 2016
   Google Scholar
• Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886-97
   Web of Science ®Google Scholar
• Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 2015;26:368-74
   PubMed Web of Science ®Google Scholar
• Ibrahim T, Farolfi A, Mercatali L, et al. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. Tumori 2013;99:1-9
   PubMed Web of Science ®Google Scholar
• Duran I, Fink MG, Bahl A, et al. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. Eur J Cancer Care 2016; doi: 10.1111/ecc.12452
   PubMedGoogle Scholar
• Lebret T, Casas A, Cavo M, et al. The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey. Eur J Cancer Care 2016; doi: 10.1111/ecc.12490
   PubMed Web of Science ®Google Scholar
• Lothgren M, Ribnicsek E, Schmidt L, et al. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm Sci Pract 2013;20:227-31
   PubMedGoogle Scholar
• Body J, Mebis J, Peeters M, et al. A time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease in Belgium. Value Health 2015;18:A485
   Web of Science ®Google Scholar
• Pedrazzoli P, Caraceni A, Beano A, et al. Results from a time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease from Italian sites. Value Health 2015;18:A485-6
   PubMed Web of Science ®Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient 2015;8:145?153
   Google Scholar
• Hernandez RK, Quigley J, Pirolli M, et al. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer 2014;22:2697-705
   PubMed Web of Science ®Google Scholar
• Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. BMJ 2007;335:24-7
   PubMed Web of Science ®Google Scholar
• Amgen. Data on file (Clinical study reports 20050103, 20050136 and 20050244)
   Google Scholar
• Amgen. Data on file
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford, UK: Oxford University Press; 2006
   Google Scholar
• International Agency for Research on Cancer, WHO. Chapter 2: Rates and rate standardization. In: N.E. Breslow and N.E. Day Eds Statistical methods in cancer research volume II: the design and analysis of cohort studies. Lyon, France: Oxford University Press; 1987, pp 48-81
   Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar